Relief Therapeutics Holding (Relief Therapeutics Holding) EBITDA Margin % : -2,059.58% (As of Jun. 2023)

View and export this data going back to 1990. Start your Free Trial

What is Relief Therapeutics Holding EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Relief Therapeutics Holding's EBITDA for the six months ended in Jun. 2023 was $-69.14 Mil. Relief Therapeutics Holding's Revenue for the six months ended in Jun. 2023 was $3.36 Mil. Therefore, Relief Therapeutics Holding's EBITDA margin for the quarter that ended in Jun. 2023 was -2,059.58%.

Relief Therapeutics Holding EBITDA Margin % Historical Data

The historical data trend for Relief Therapeutics Holding's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding EBITDA Margin % Chart

Relief Therapeutics Holding Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBITDA Margin %

Get a 7-Day Free Trial

-45.79

-1,002.52

-827.23

Relief Therapeutics Holding Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EBITDA Margin %	Get a 7-Day Free Trial															-	-562.73	-780.13	-880.90	-2,059.58

Competitive Comparison of Relief Therapeutics Holding's EBITDA Margin %

For the Biotechnology subindustry, Relief Therapeutics Holding's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Relief Therapeutics Holding's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's EBITDA Margin % falls into.

Relief Therapeutics Holding EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Relief Therapeutics Holding's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-53.993	/	6.527
	=	-827.23 %

Relief Therapeutics Holding's EBITDA Margin % for the quarter that ended in Jun. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-69.14	/	3.357
	=	-2,059.58 %

Relief Therapeutics Holding (OTCPK:RLFTF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Relief Therapeutics Holding EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Relief Therapeutics Holding (Relief Therapeutics Holding) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (OTCPK:RLFTF) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

RLFTY:USA RLFz:UK RLF:Switzerland

Address

Avenue de Secheron 15, Fondation EIP, Batiment, Geneva, CHE, CH-1202

Website

https://www.relieftherapeutics.com

Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Geographically group generates the majority of its revenue from Europe.